FDA Grants Priority Review to Ramucirumab for Advanced Gastric Cancer

Share this content:

Eli Lilly and Company announced that the FDA has granted Priority Review to the Biologics License Application (BLA) for ramucirumab (IMC-1121B) as a single-agent treatment for advanced gastric cancer following disease progression after initial chemotherapy. Ramucirumab is a human, receptor-targeted antibody that specifically blocks the vascular endothelial growth factor (VEGF) receptor 2 and inhibits the downstream signaling involved in the formation and maintenance of aberrant blood vessels that supply blood to tumors.

Related: Gastrointestal Cancers Resource Center

The submission was based on data from REGARD, a global, randomized, double-blind Phase 3 study of ramucirumab plus best supportive care compared to placebo plus best supportive care as a treatment in patients with advanced gastric cancer, including adenocarcinomas of the gastro-esophageal junction following progression after initial chemotherapy.

Ramucirumab has also been studied in combination with paclitaxel for the treatment of advanced gastric cancer in the Phase 3 RAINBOW trial. The combination-therapy ramucirumab data from that trial will be the basis for separate regulatory applications. Lilly is also conducting three separate Phase 3 trials of ramucirumab in colorectal, hepatocellular and lung cancer in 2014.

For more information call (800) 545-5979 or visit Lilly.com.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs